BTIG Research Initiates Coverage on Agios Pharmaceuticals Inc(NASDAQ:AGIO). The shares have been rated Neutral. The rating by BTIG Research was issued on Aug 19, 2016.
In a different note, On Jun 13, 2016, Canaccord Genuity said it Upgrades its rating on Agios Pharmaceuticals Inc. In the research note, the firm Raises the price-target to $50.00 per share. The shares have been rated ‘Buy’ by the firm. On Jun 13, 2016, JP Morgan said it Upgrades its rating on Agios Pharmaceuticals Inc. In the research note, the firm Raises the price-target to $50.00 per share. The shares have been rated ‘Overweight’ by the firm.
Agios Pharmaceuticals Inc (AGIO) shares turned negative on Mondays trading session with the shares closing down -0.27 points or -0.71% at a volume of 3,05,108. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $38.35. The peak price level was also seen at $38.35 while the days lowest was $37.37. Finally the shares closed at $37.76. The 52-week high of the shares is $99.4625 while the 52-week low is $33.5. According to the latest information available, the market cap of the company is $1,437 M.
Agios Pharmaceuticals Inc(AGIO) last announced its earnings results on Aug 4, 2016 for Fiscal Year 2016 and Q2.Company reported revenue of $6.98M. Analysts had an estimated revenue of $39.62M. Earnings per share were $-1.47. Analysts had estimated an EPS of $-0.48.
Several Insider Transactions has been reported to the SEC. On Jul 27, 2016, Lewis Clayton Jr. Cantley (director) sold 2,504 shares at $42.79 per share price.Also, On Jun 10, 2016, Scott Biller (Chief Scientific Officer) sold 27,500 shares at $65.00 per share price.On Dec 17, 2015, John Duncan Higgons (Chief Operating Officer) sold 20,000 shares at $50.09 per share price, according to the Form-4 filing with the securities and exchange commission.
Agios Pharmaceuticals Inc. (Agios) is a biopharmaceutical company. The Company is engaged in the discovery and development of orally available small molecule medicines for the treatment of cancer and rare genetic disorders (RGDs) of metabolism using cellular metabolism as a platform. It is also engaged in the identification and validation of altered metabolic pathways within abnormal cells. Its products include AG-221 AG-120 and AG-348. Its lead product AG-348 in the RGD program is an orally available small molecule that targets pyruvate kinase-R for the treatment of pyruvate kinase deficiency. AG-221 is potent inhibitor of the mutated IDH2 protein being developed for the treatment hematological malignancies and advanced solid tumors. AG-120 is an orally available selective potent inhibitor of the mutated IDH1 protein being developed for the treatment hematological malignancies and advanced solid tumors.